{"filing":{"accession_number":"0001193125-26-390877","cik":"0001612042","ticker":"ASND","company_name":"Ascendis Pharma A/S","form":"6-K","filing_date":"2026-09-14","report_date":"2026-09-14","primary_document":"d183438d6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1612042/000119312526390877/d183438d6k.htm"},"events":[{"id":33400,"run_id":30708,"accession_number":"0001193125-26-390877","anchor_item_number":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"summary":"Ascendis announced on September 14, 2026, that it will regain exclusive rights to develop, manufacture, and commercialize TransCon technology-based products in metabolic and cardiovascular diseases following termination of its collaboration agreement with Novo Nordisk A/S. This represents a material change in control and reversion of significant intellectual property rights, including rights to once-monthly TransCon Semaglutide, with no continuing financial obligations between parties—a substantive alteration of the registrant's asset portfolio and commercial position.","company_name":"Ascendis Pharma A/S","ticker":"ASND","filing_date":"2026-09-14","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":36847,"accession_number":"0001193125-26-390877","item_number":null,"item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"Ascendis announced on September 14, 2026, that it will regain exclusive rights to develop, manufacture, and commercialize TransCon technology-based products in metabolic and cardiovascular diseases following termination of its collaboration agreement with Novo Nordisk A/S. This represents a material change in control and reversion of significant intellectual property rights, including rights to once-monthly TransCon Semaglutide, with no continuing financial obligations between parties—a substantive alteration of the registrant's asset portfolio and commercial position.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-15T10:04:01.609745+00:00","company_name":"Ascendis Pharma A/S","ticker":"ASND","filing_date":"2026-09-14"}]}